Police & Firemen s Retirement System of New Jersey Buys 3,155 Shares of Dyne Therapeutics, Inc. $DYN

Police & Firemen s Retirement System of New Jersey lifted its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 18.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,334 shares of the company’s stock after acquiring an additional 3,155 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in Dyne Therapeutics were worth $194,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Dyne Therapeutics by 22.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,247 shares of the company’s stock worth $201,000 after purchasing an additional 3,496 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Dyne Therapeutics during the 1st quarter valued at $1,031,000. XTX Topco Ltd bought a new position in shares of Dyne Therapeutics during the 1st quarter valued at $330,000. Privium Fund Management B.V. boosted its stake in shares of Dyne Therapeutics by 35.4% in the 1st quarter. Privium Fund Management B.V. now owns 27,566 shares of the company’s stock worth $288,000 after buying an additional 7,200 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Dyne Therapeutics by 10.5% in the first quarter. Vanguard Group Inc. now owns 7,406,344 shares of the company’s stock worth $77,470,000 after acquiring an additional 702,418 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $21.92 on Friday. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $31.29. The stock has a market cap of $3.13 billion, a price-to-earnings ratio of -5.68 and a beta of 1.16. The company’s 50 day moving average is $17.73 and its two-hundred day moving average is $13.70.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.05. As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox sold 2,640 shares of the firm’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $13.41, for a total transaction of $35,402.40. Following the sale, the chief executive officer directly owned 199,539 shares of the company’s stock, valued at $2,675,817.99. This trade represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 20.77% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on DYN. Royal Bank Of Canada increased their target price on Dyne Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Raymond James Financial raised shares of Dyne Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $31.00 to $35.00 in a research report on Monday, August 25th. Sanford C. Bernstein reissued a “market perform” rating and issued a $21.00 price objective on shares of Dyne Therapeutics in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Wednesday, October 8th. Finally, Lifesci Capital upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Four research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.47.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.